Sleep Disorders: Insomnia, Sleep Apnea, Restless Leg Syndrome, Bruxism, Narcolepsy and Sleepwalking

Published by: Trimark Publications

Published: Mar. 1, 2009 - 292 Pages

Table of Contents

1. Overview

1.1 Statement of Report

1.2 About This Report

1.3 Scope of the Report

1.4 Methodology

1.5 Executive Summary

1.6 U.S. Sleep Market

1.6.1 Sleep Drugs Market in the U.S.

1.6.2 U.S. Sleep Apnea Devices Market

1.6.3 U.S. Market for Mattresses and Other Related Products

1.6.4 Sleep Laboratories in the U.S.

1.6.4.1 Locate Sleep Centers in the U.S.

1.7 Future of Sleep Drugs

1.7.1 Sleep Drugs for Jet Lag and Shift Work

1.7.2 Sleep Drugs for Age-related Sleep Issues

1.7.3 Sleep Drugs for Those Who Cannot Sleep Through the Night

1.7.4 Sleep Drugs for Restless Leg Syndrome

1.7.5 Sleep Drugs for Insomnia

1.7.6 Sleep Drugs for Sleep Apnea

2. Introduction to Sleep Disorders

2.1 Sleep Disorders Overview

2.1.1 Sleep Facts from the U.S.

2.1.2 Consequences of Sleep Disorder Problems

2.2 Physiology of Sleep

2.2.1 Sleep Stages

2.2.2 Neutral Control of Sleep

2.3 Current Understanding of Sleep Disorders

2.3.1 Hypersomnia

2.3.1.1 Causes of Hypersomnia

2.3.1.2 Demographics of Hypersomnia

2.3.1.3 Treatment for Hypersomnia

2.4 Obstructive Sleep Apnea (OSA)

2.4.1 Causes of Sleep Apnea

2.4.2 Symptoms of Sleep Apnea

2.4.3 Demographics of Sleep Apnea

2.4.4 Diagnosis of Sleep Apnea

2.4.5 Treatments

2.4.5.1 Positional Therapy

2.4.5.2 Behavioral Therapy—Weight Loss

2.4.5.3 Oral Appliances

2.4.5.4 Surgery for Sleep Apnea

2.4.5.5 Nasal Continuous Positive Airway Pressure (CPAP) Therapy

2.4.5.6 Medications for Sleep Apnea

2.4.6 The National Ambulatory Medical Care Survey on Sleep Apnea

2.4.6.1 Age and Sleep Apnea in Men

2.5 Narcolepsy

2.5.1 Demographics of Narcolepsy

2.5.2 Causes of Narcolepsy

2.5.3 Symptoms of Narcolepsy

2.5.4 Diagnosis of Narcolepsy

2.5.5 Treatment for Narcolepsy

2.6 Insomnia

2.6.1 Causes of Insomnia

2.6.2 Symptoms of Insomnia

2.6.3 Demographics of Insomnia

2.6.4 Diagnosis of Insomnia

2.6.5 Insomnia and Obesity

2.6.6 Treatments for Insomnia

2.6.6.1 Behavioral Treatment for Insomnia

2.6.6.2 Treating Insomnia with Medications

2.6.6.3 Alternative Remedies for Insomnia

2.6.7 Insomnia Market

2.6.8 National Sleep Foundations’ “Sleep In America Poll”

2.6.8.1 Benzodiazepines

2.6.8.2 The Short-term Gold Standard

2.6.8.3 Emerging Players

2.6.8.4 Insomnia Market Indicators

2.6.8.5 Newer Sedative Drugs for Insomnia in 2008

2.7 Restless Legs Syndrome

2.7.1 Demographics of RLS

2.7.2 Causes of RLS

2.7.3 Symptoms of RLS

2.7.4 Diagnosis of RLS

2.7.5 Treatments for RLS

2.7.5.1 Lifestyle Changes and RLS

2.7.5.2 Treating RLS with Pharmaceuticals

2.8 Circadian Rhythm Disorders

2.8.1 Causes of Circadian Rhythm Disorders

2.8.2 Symptoms

2.8.3 Demographics of Circadian Rhythm Disorders

2.8.4 Diagnosis of Circadian Rhythm Disorders

2.8.5 Treatments for Circadian Rhythm Disorders

2.9 Parasomnias

2.9.1 Nightmare Disorder

2.9.2 Sleep Terror Disorder

2.9.3 Sleep Walking Disorder

2.9.4 Demographics of Parasomnias

2.9.5 Causes and Symptoms of Parasomnias

2.9.6 Diagnosis

2.9.7 Treatment for Parasomnias

3. Drugs Used for Sleep Disorders

3.1 Estazolam

3.2 Flurazepam (Dalmane)

3.3 Temazepam

3.4 Triazolam

3.5 Zopiclone (Inovane)

3.6 Nonbenzodiazepine Hypnotics

3.6.1 Eszopiclone (Lunesta)

3.6.2 Zaleplon (Sonata)

3.6.3 Zolpidem (Ambien, Ambien CR)

3.7 Pineal Gland Hormones

3.7.1 Melatonin

3.7.2 Ramelteon (Rozerem)

3.8 Antihistamines

3.8.1 Benadryl (Diphenhydramine)

3.8.2 Doxylamine

3.9 Antidepressants

3.9.1 Amitriptyline (Elavil)

3.9.2 Nortriptyline (Pamelor)

3.9.3 Nefazodone (Serzone)

3.9.4 Trazodone (Desyrel)

3.9.5 Indiplon

3.9.6 Gaboxadol

3.9.7 Silenor

3.10 Other Substances

3.10.1 Lavender

3.10.2 Passion Flower

3.10.3 Ashwagandha

3.10.4 Catnip

3.10.5 Kava (Piper methysticum)

3.10.6 Valerian

3.11 Aromatherapy

3.12 Some OTC Sleep Gadgets in the Market

3.12.1 Dreamate™

3.12.2 Anti-snoring Pillow

3.12.3 Nasal Dialators

3.12.4 Nasal Strips

3.12.5 Snore Stopper

3.12.6 SleepMate

3.12.7 Antisnor Therapeutic Ring

3.12.8 Ayurvedic Treatment for Insomnia

3.12.9 Yoga for Sleep Disorders

3.12.10 Meditation for Sleep Disorders

3.12.11 Hypnosis for Sleep Disorders

3.13 Homeopathic Treatment for Sleep Disorders

3.13.1 Belladonna

3.13.2 Nux vomica

3.13.3 Chamomilla

3.13.4 Gelsemium

3.13.5 Cannabis Indica

4. A Guide to Better Sleep

4.1 The Normally Required Sleep

4.2 Sleep and Driving

4.3 Tips to Avoid Drowsy Driving

4.4 Tips to Find whether One has Sleep Disorders

4.5 A Good Night’s Sleep

5. Sleep Laboratories

6. Profiles of Companies and Their Product Offering

6.1 Device Companies (CPAP and Other)

6.1.1 AEIOmed, Inc. and Product Offerings

6.1.2 Chad Therapeutics, Inc. and Product Offerings

6.1.3 Compumedics Ltd. and Product Offerings

6.1.4 Puritan Bennett (Covidien) and Product Offerings

6.1.5 ResMed Corporation and Product Offerings

6.1.6 Respironics, Inc. (Philips)

6.1.7 CleveMed and Product Offerings

6.1.8 SomnoMed Ltd. and Product Offerings

6.2 Pharmaceutical (Prescription and OTC) Companies

6.2.1 Acadia Pharmaceuticals, Inc.

6.2.1.1 Pimavanserin for the Treatment of Parkinson’s Disease Psychosis

6.2.1.2 Pimavanserin as a Co-therapy for Schizophrenia

6.2.1.3 ACP-104 for the Treatment of Schizophrenia

6.2.1.4 Pimavanserin for the Treatment of Sleep Maintenance Insomnia

6.2.1.5 Neuropathic Pain

6.2.1.6 Glaucoma

6.2.2 Actelion Ltd.

6.2.2.1 Actelion’s Tracleer®

6.2.2.2 Tracleer in Digital Ulcers

6.2.2.3 Actelion’s Ventavis®

6.2.2.4 Actelion’s Zavesca®

6.2.2.5 Actelion’s Focus on Sleep and Sleep Disorders

6.2.2.6 The Orexin System

6.2.2.7 Almorexant in Clinical Development

6.2.3 Arena Pharmaceuticals, Inc.

6.2.3.1 Arena’s R&D Programs

6.2.3.2 Arena Pharmaceuticals’ Development Pipeline

6.2.3.3 Locaserin Hydrochloride for Obesity

6.2.3.4 APD125 for Insopmnia

6.2.4 Cephalon, Inc.

6.2.5 Eli Lilly and Company

6.2.5.1 Eli Lilly’s Product Acquisitions, 2007

6.2.6 GlaxoSmithKline Plc

6.2.7 King Pharmaceuticals, Inc. and Product Offerings

6.2.7.1 King Pharmaceutical’s R&D

6.2.7.2 King Pharmaceutical’s Manufacturing

6.2.7.3 King Pharmaceutical’s Financial Highlights

6.2.8 Neurogen Corporation

6.2.8.1 Neurogen’s Insomnia Products

6.2.8.2 Positive Results in Phase IIb Studies in Chronic Insomnia

6.2.8.3 Positive Results in Phase IIb Studies with Adipiplon

6.2.8.4 Study 202—Primary Endpoint Sleep Maintenance

6.2.8.5 Study 203—Primary Endpoint Sleep Onset

6.2.8.6 Transient Insomnia

6.2.8.7 Study Results

6.2.8.8 Study Design

6.2.9 Neurocrine Biosciences, Inc.

6.2.9.1 Neurocrine’s Pipeline—GnRH Antagonists

6.2.9.2 Corticotropin Releasing Factor (CRF1) Receptor Antagonists

6.2.9.3 Urocortin 2 for Congestive Heart Failure (CHF)

6.2.9.4 Neurocrine’s Research Programs

6.2.9.5 Indiplon

6.2.10 Pfizer, Inc. and Product Offerings

6.2.10.1 Lipitor

6.2.10.2 Norvasc

6.2.10.3 Celebrex

6.2.10.4 Lyrica

6.2.10.5 Viagra

6.2.10.6 Xalatan/Xalacom

6.2.10.7 Zyrtec/Zyrtec D

6.2.10.8 Detrol/Detrol LA

6.2.10.9 Camptosar

6.2.10.10 Zyvox

6.2.10.11 Chantix/Champix

6.2.10.12 Geodon/Zeldox

6.2.10.13 Genotropin

6.2.10.14 Vfend

6.2.10.15 Sutent

6.2.10.16 Caudet

6.2.10.17 Zoloft

6.2.10.18 Zithromax/Zmax

6.2.10.19 Aricept

6.2.10.20 Replax

6.2.10.21 Revatio

6.2.10.22 Aromasin

6.2.10.23 Eraxis/Ecalta

6.2.10.24 Indiplon

6.2.10.25 Halcion (Triazolam)

6.2.11 Sanofi Aventis

6.2.11.1 Sanofi’s Pharmaceutical Business in 2007

6.2.11.2 Sanofi’s Human Vaccine Business in 2007

6.2.11.3 Ambien CR

6.2.11.4 Ambien

6.2.12 Schering-Plough Corporation

6.2.13 Sepracor, Inc.

6.2.14 SleepMed, Inc.

6.2.14.1 Home Sleep Disorders Sleep Laboratory Partnership Services

6.2.14.2 SleepMed’s Self-test for Sleep Disorders

6.2.14.3 Sleepiness Scale

6.2.15 Somaxon Pharmaceuticals, Inc.

6.2.15.1 Silenor (Doxepin HCl Tablets)—A Successful Clinical Development Program

6.2.16 Takeda Pharmaceutical Company Ltd.

6.2.17 Takeda Pharmaceuticals North America, Inc.

6.2.17.1 Rozerem

6.2.18 Vanda Pharmaceuticals, Inc.

6.2.19 Wyeth

6.2.20 Valeant Pharmaceuticals, Inc.

List of Appendix

Appendix 1: Sleep-related Disorders in the U.S.

Appendix 1.1: Sleep and Smoking

Appendix 1.2: Sleep and Alcohol Use

Appendix 1.3: Sleep and Physical Inactivity

Appendix 1.4: Sleep and Obesity

Appendix 2: Chronic Shift Work Sleep Disorder and Treatment with Modafinil

Appendix 3: Sleep Centers and Sleep Labs

Appendix 3.1: Tests Performed in the Sleep Laboratories

Appendix 4: Obesity

Appendix 4.1: U.S. Obesity Trends, 2007

Appendix 4.2: Economic Consequences of Obesity

Appendix 4.3: Childhood Overweight and Obesity

Appendix 4.4: Prevalence of Overweight and Obesity in a U.S. Pediatric Surgical Population

Appendix 5: Sleep Disorders and Sleep Deprivation

Appendix 5.1: Sleep Physiology

Appendix 5.2: Two Types of Sleep

Appendix 5.3: NREM and REM Sleep Cycles

Appendix 5.4: Four Stages of NREM Sleep

Appendix 5.5: Stage I Sleep

Appendix 5.6: Stage II Sleep

Appendix 5.7: Stages III and IV—Slow Wave Sleep

Appendix 5.8: REKM Sleep

Appendix 5.9: Sleep-Wake Regulation

Appendix 5.10: Sleep-generating System in the Brain Stem

Appendix 5.11: Wake-generating System in the Brain Stem

Appendix 5.12: Circadian Rythms

Appendix 5.13: Change of Sleep Patterns with Age

Appendix 5.14: Sleep Architecture in Young Children

Appendix 5.15: Sleep Architecture in Adolescents

Appendix 5.16: Sleep Architecture in Adults

Appendix 5.17: Gender Difference and Sleep Architecture

Appendix 5.18: Sleep Architecture in Elderly People

Appendix 6: American Sleep Association

Appendix 6.1: Clinical Trials

Appendix 6.2: Risks in Clinical Trials

Appendix 6.3: Ideas for Clinical Trials

Appendix 6.4: Sponsors of Clinical Trials

Appendix 6.5: Placebo

Appendix 6.6: Control Group

Appendix 6.7: Different Phases of Clinical Trials

Appendix 7: Deprived Sleep and Automobile Crashes in the U.S.

Appendix 7.1: Biology of Human Sleep and Sleepiness

Appendix 7.2: Crash Characteristics

Appendix 7.3: Countermeasures

Appendix 7.4: Panel Recommendations

Appendix 7.5: Sleepiness Impairs Performance

Appendix 7.6: Causes of Sleepiness/Drowsy Driving

Appendix 7.7: Sleep Restriction or Loss

Appendix 7.8: Job-related Sleep Restrictions

Appendix 7.9: Personal Demands and Lifestyle Choices

Appendix 7.10: Sleep Fragmentation

Appendix 7.11: Characteristics of Drowsy-driving Crashes

Appendix 7.12: The Problem Occurs during Late Night Hours

Appendix 7.13: Crashes Occur on a High-speed Road

Appendix 7.14: More Single Occupant Crashes

Appendix 7.15: Consumption of Alcohol Increases Drowsiness

Appendix 7.16: Population Groups at Highest Risk of Road Crashes

Appendix 8: Sleep-related Organizations

Appendix 8.1: American Sleep Apnea Association

Appendix 8.2: The American Sleep Association

Appendix 8.3: National Sleep Foundation

Appendix 8.4: National Center on Sleep Disorders Research (NCSDR)

Appendix 8.4.1: Research

Appendix 8.4.2: Training

Appendix 8.4.3: Technology Transfer

Appendix 8.4.4: Coordination

Appendix 8.5: American Academy of Sleep Medicines

Appendix 8.6: International Restless Leg Syndrome Study Group

Appendix 8.7: The Movement Disorder Society

INDEX OF FIGURES

Figure 1.1: Total Market for Leading Sleep Drugs, 2007

Figure 1.2: Sleep Product’s Market Share, 2007

Figure 1.3: Percent Market Share of Leading CPAP Devices, 2008

Figure 1.4: U.S. Rx and OTC Sleeping Pills Market, 2003-2007

Figure 1.5: U.S. CPAP Sleep Apnea Devices Market, 2003-2007

Figure 1.6: U.S. Mattresses and Foundations Retail Market, 2003-2007

Figure 1.7: U.S. Sleep Lab Revenues, 2003-2007

Figure 1.8: Number of Accredited Sleep Labs in the U.S., 2003-2007

Figure 1.9: U.S. Growth of Sleep Center Beds, 2007-2009

Figure 1.10: Circadin’s Effect on the Improvement in Quality of Sleep

Figure 2.1: Hours of Sleep in a Sample U.S. Population, 2008

Figure 2.2: Treatment Effects on Patients with Hypersomnia

Figure 2.3: Adults with Sleep Apnea Symptoms who Sought Medical Care in the U.S., 2006

Figure 2.4: Sleep Apnea Percentage by Medical Specialty as Reported by NAMCS

Figure 2.5: NAMCS Ages of Sleep Apnea Patients

Figure 2.6: Age-specific Prevalence of Obstructive Sleep Apnea Diagnosed

Figure 2.7: Prevalence of Sleep Aid Use by Age Group in the U.S., 1998-2006

Figure 2.8: Percentage of Sleep Aid Users Younger than 45 Years Old in the U.S., 1998-2006

Figure 2.9: Prevalence of Mental Health Diagnoses Made in First Sleep Aid Users by Provider Type

Figure 2.10: Common Symptoms of Insomnia

Figure 2.11: Insomnia Patient Population, 2007

Figure 2.12: Obesity Prevalence by Age and Sex in the U.S., 2005-2006

Figure 2.13: Prevalence of Obesity in U.S. Women by Age and Race/Ethnicity, 2005-2006

Figure 2.14: The Globally Growing Market for Insomnia, 2001-2006

Figure 2.15: Global Prescription for Insomnia Products, 2001-2006

Figure 2.16: Global Sales of Insomnia Drugs, 2007

Figure 2.17: Global Insomnia Market, 2005-2009

Figure 2.18: Frequency of Insomnia Symptoms in the U.S. Adult Population

Figure 2.19: U.S. Sleep Market—Under-Penetrated

Figure 2.20: U.S. Sleep Market Growth, 2009

Figure 2.21: Time to Sleep for RLS Sufferers

Figure 2.22: Times RLS Sufferers Woken at Night

Figure 2.23: RLS Sufferers Referred to Specialist by Country

Figure 3.1: Dalmane’s Market, 2005-2007

Figure 3.2: Global Market for Lunesta, 2005-2007

Figure 3.3: Sonata’s (Zaleplon) Sales, 2005-2007

Figure 3.4: Total Sales for Four Leading Brands of Sleeping Pills, 2007

Figure 3.5: WASO

Figure 5.1: Number of Accredited Sleep Labs in the U.S., 2003-2007

Figure 5.2: Sleep Monitoring Revenue Distribution by Provider Type in the U.S., 2006

Figure 5.3: U.S. Sleep Lab Revenues, 2003-2007

Figure 6.1: Chad’s Business for the Six months ended September, 2006 and 2007

Figure 6.2: Chad’s R&D Expenditure for the Six Months Ended September, 2006 and 2007

Figure 6.3: Chad’s Business in Geographic Region/Country for Six Months Ended September, 2007

Figure 6.4: Compumedics’ Revenue, 2003-2008

Figure 6.5: Compumedics’ R&D Expenditure, 2007 and 2008

Figure 6.6: Compumedics’ Business Revenue from the U.S., 2003-2008

Figure 6.7: Compumedics’ Global Sleep Diagnostic Market, 2008

Figure 6.8: Compumedics’ Global Brain Research Market, 2008

Figure 6.9: Compumedics’ Global Neurodiagnostics Market, 2008

Figure 6.10: Compumedics’ Global Neuromedical Supplies Market, 2008

Figure 6.11: Compumedics’ Global Doppler Ultrsound Market, 2008

Figure 6.12: Covidien’s Medical Device Business Sales, 2005-2007

Figure 6.13: Covidien’s Pharmaceutical Products Business Sales, 2005-2007

Figure 6.14: Covidien’s Imaging Solutions Business Sales, 2005-2007

Figure 6.15: Covidien’s Medical Supplies Business Sales, 2005-2007

Figure 6.16: Covidien’s Retail Products Business Sales, 2005-2007

Figure 6.17: Covidien’s Net Sales by Geographic Area, 2005-2007

Figure 6.18: Covidien’s R&D Expenditure, 2005-2007

Figure 6.19: ResMed’s Percent Net Revenue from North and Latin America, 2006-2008

Figure 6.20: ResMed’s Percent Net Revenue from Europe, 2006-2008

Figure 6.21: ResMed’s Percent Net Revenue from Asia Pacific, 2006-2008

Figure 6.22: Number of Employees in ResMed and its Subsidiaries, 2008

Figure 6.23: ResMed’s Consolidated Statement of Income Data, 2004-2008

Figure 6.24: ResMed’s R&D Expenditure, 2004-2008

Figure 6.25: Respironics’ Business, 2006 and 2007

Figure 6.26: SomnoMed’s OSA Global Market Size Projection, 2007 and 2008

Figure 6.27: Growth Projection for SomnoMed MAS, 2005-2010

Figure 6.28: Acadia’s Revenue, 2003-2007

Figure 6.29: Acadia’s R&D Expenses, 2003-2007

Figure 6.30: Actelion’s Sales Revenue from Three of its Brands, 2007

Figure 6.31: Actelion’s Revenue, 2007-2008

Figure 6.32: Actelion’s Net Revenues and Net Income, 2006 and 2007

Figure 6.33: Actelion’s Sales Revenue, 2006-2008

Figure 6.34: Arena’s Research Expenditure, 2005-2007

Figure 6.35: Arena’s Revenue, 2003-2007

Figure 6.36: Arena’s Revenue from Partnered Programs, 2005-2007

Figure 6.37: Provigil Sales Revenue, 2007

Figure 6.38: Cephalon’s Percent Net Sales of Provigil, Fentora and Actiq, 2007

Figure 6.39: Cephalon’s Consolidated Total Revenue, 2003-2007

Figure 6.40: Cephalon’s R&D Expenditure, 2006-2007

Figure 6.41: Cephalon’s Total Sales Revenue of Products by Segment, 2007

Figure 6.42: Eli Lilly’s Products Launched this Decade Contributed $6.0 Billion, 2007

Figure 6.43: Eli Lilly’s Six Products Exceeded $1.0 Billion in Net Sales, 2007

Figure 6.44: Eli Lilly’s Growth Across Therapeutic Areas, 2007

Figure 6.45: Eli Lilly’s Gross Margin, 2003-2007

Figure 6.46: Eli Lilly’s Increased R&D Investment, 2003-2007

Figure 6.47: GSK’s Top Five Consumer Healthcare Products by Turnover, 2007

Figure 6.48: GSK’s Employee Numbers by Region, 2007

Figure 6.49: GSK’s Respiratory Products’ Turnover, 2007

Figure 6.50: GSK’s Central Nervous System Products’ Turnover, 2007

Figure 6.51: GSK’s HIV Products’ Turnover, 2007

Figure 6.52: GSK’s Herpes Products’ Turnover, 2007

Figure 6.53: GSK’s Metabolic Products’ Turnover, 2007

Figure 6.54: GSK’s Vaccines’ Turnover, 2007

Figure 6.55: GSK’s Cardiovascular and Urogenital Products’ Turnover, 2007

Figure 6.56: GSK’s Oncology and Emesis Products’ Turnover, 2007

Figure 6.57: GSK’s Pharmaceutical Turnover from the U.S. and Europe, 2007

Figure 6.58: GSK’s Pharmaceuticals Turnover in the International Market, 2007

Figure 6.59: GSK’s Total Turnover of Pharmaceuticals and Consumer Healthcare, 2005-2007

Figure 6.60: GSK’s R&D Expenditure, 2005-2007

Figure 6.61: King’s Net Sales of Neuroscience Products, 2007

Figure 6.62: King’s Net Sales of Hospital Products, 2007

Figure 6.63: King’s Net Sales of Acute Care Products, 2007

Figure 6.64: King’s Net Sales of Cardiovascular/Metabolic Products, 2007

Figure 6.65: King’s Research Expenditure, 2005-2007

Figure 6.66: Neurogen’s R&D Expenditure, 2005-2007

Figure 6.67: Funding by Neurogen’s Collaborative Partners in R&D, 2005-2007

Figure 6.68: Neurogen’s Business, 2003-2007

Figure 6.69: Mean LPS in Minutes for Each Arm of the Study

Figure 6.70: Neurocrine’s Total Revenue, 2002-2006

Figure 6.71: Neurocrine’s R&D Expenditure, 2002-2006

Figure 6.72: Pfizer’s Revenue, 2005-2007

Figure 6.73: Pfizer’s R&D Expenditure, 2005-2007

Figure 6.74: Pfizer’s Sales Revenues from its Pharmaceutical Medicines, 2007

Figure 6.75: Pfizer’s Revenue from Pharmaceutical Medicines, 2007

Figure 6.76: Pfizer’s Sales Revenue from its Pharmaceutical Products, 2007

Figure 6.77: Pfizer’s Sales Revenue from its Pharmaceutical Products, 2007

Figure 6.78: Pfizer’s Sales Revenue from its Pharmaceutical Products, 2007

Figure 6.79: Global Market for Pharmaceutical Medicines by Disease Segment, 2012

Figure 6.80: Pfizer’s Revenue by Business Segments, 2005-2007

Figure 6.81: Pfizer’s Revenue by Segment, 2007

Figure 6.82: Sanofi’s Business, 2004-2007

Figure 6.83: Sanofi’s Business, 2007

Figure 6.84: Sanofi’s Top Five Pharmaceutical’s Sales, 2007

Figure 6.85: Sanofi’s Global Sales of Flavix, 2007

Figure 6.86: Sanofi’s Human Vaccine Business, 2007

Figure 6.87: Schering-Plough’s Consolidated Sales Revenue, 2005-2007

Figure 6.88: Schering-Plough’s Human Prescription Pharmaceutical Sales, 2005-2007

Figure 6.89: Schering-Plough’s Animal Health Product’s Revenue, 2005-2007

Figure 6.90: Schering-Plough’s Consumer Healthcare Revenue, 2005-2007

Figure 6.91: Schering-Plough’s R&D Expenditure, 2005-2007

Figure 6.92: Schering-Plough’s Sales Revenue from Top Seven Human Prescription Pharmaceuticals, 2007

Figure 6.93: Sepracor’s Total Revenues, 2003-2007

Figure 6.94: Sepracor’s Revenue from Lunesta, 2005-2007

Figure 6.95: Sepracor’s Revenue from Xoponex, 2005-2007

Figure 6.96: Sepracor’s Employee Distribution, 2007

Figure 6.97: Somaxon’s R&D Expenditure, 2004-2007

Figure 6.98: Takeda’s Business, 2006-2008

Figure 6.99: Takeda’s Net Sales by Region, 2006-2008

Figure 6.100: Takeda’s R&D Expenditure, 2006-2008

Figure 6.101: Takeda’s Performance in Europe, 2003-2007

Figure 6.102: Net Sales of Actos, 2003-2007

Figure 6.103: Total Global Pharmaceutical Market by Region, 2007

Figure 6.104: Takeda’s Net Sales of International Strategic Products, 2007

Figure 6.105: Takeda’s Net Sales by Region, 2007

Figure 6.106: Wyeth’s Sales Revenue, 2006 and 2007

Figure 6.107: Wyeth’s Pharmaceutical Sales Revenue, 2007

Figure 6.108: Wyeth’s Business, 2004-2007

Figure 6.109: Wyeth’s R&D Expenditure, 2004-2007

Figure 6.110: Wyeth’s Revenue by Segment, 2004-2007

Figure 6.111: Valeant Pharmaceuticals’ Total Revenues, 2003-2007

Figure 6.112: Valeant Pharmaceutical’s R&D Expenditure, 2003-2007

Figure 6.113: Valeant Pharmaceuticals’ Total Turnover in Neurology Products, 2005-2007

Figure 6.114: Valeant Pharmaceuticals’ Total Turnover for its Dermatology Products, 2005-2007

Figure 6.115: Valeant Pharmaceuticals’ Total Turnover for Infectious Diseases’ Products, 2005-2007

Figure A1.1: Age-adjusted Percentage of Hours of Sleep in a Day Among Adults in the U.S., 2006

Figure A1.2: Age-adjusted Percentage of Adults who Currently Smoked Cigarettes and Age-adjusted Percentage who had Five or More Drinks in a Day in the U.S., 2004-2005

Figure A1.3: Age-adjusted Percentage of Adults who were Physically Inactive and Age-adjusted Percentage who were Obese by Usual Hours of Sleep in a Day in the U.S., 2004-2006

Figure A2.1: Mean Change from Baseline to Final Visit in Functional Outcomes of FOSQ Domain Scores by Treatment Group

Figure A4.1: Prevalence of Obesity Among Adult Men and Women, 2005 and 2006

Figure A4.2: Obesity Prevalence by Age and Sex in the U.S., 2006

Figure A4.3: Trends in Obesity by Sex 20 Years and Older in the U.S., 2000-2006

Figure A4.4: Prevalence of Obesity among Males by Age, Race/Ethnicity in the U.S., 2005-2006

Figure A4.5: Prevalence of Obesity in Women by Age, Race/Ethnicity in the U.S., 2005-2006

Figure A4.6: Childhood Obesity in LA County, 2001-2010

Figure A4.7: American Society of Anesthesiologists (ASA) Classification by Weight Group

Figure A4.8: Age Group and Gender-specific Prevalence (%) of Overweight and Obesity

Figure A5.1: Progression of Sleep States across a Single Night in Young Adult

Figure A5.2: Characteristic EEG Activity of Each of the Four Stages of NREM Sleep

Figure A7.1: Time of Occurrence of Crashes for 25 Years of Age or Younger

Figure A7.2: Time of Occurrence of Crashes for Drivers between 25 and 46 Years of Age

Figure A7.3: Time of Occurrence of Crashes for Drivers between 45 and 66 Years of Age

Figure A7.4: Time of Occurrence of Crashes for Drivers older than 65 Years

Figure A7.5: Interaction between Alcohol and Sleepiness

Figure A7.6: Percent Crashes by the Young Men

INDEX OF TABLES

Table 1.1: Sleep Center Locations in New York

Table 2.1: Drugs of Short and Long-acting Hypnotics

Table 2.2: Characteristics of Patients with Sleep Apnea in the NAMCS Database

Table 2.3: Prevalence of Sleep Apnea

Table 2.4: The Hallmark Symptoms of Insomnia

Table 2.5: The Four New Currently Available Sleeping Pills, 2008

Table 2.6: Cost of Newer Insomnia Drugs and Selected Older Ones, 2008

Table 6.1: ResMed’s Product Portfolio, 2008

Table 6.2: Acadia’s Programs, 2007

Table 6.3: Actelion’s Products in the Market, 2007

Table 6.4: Actelion’s Clinical Development Pipeline, 2007

Table 6.5: Actelion’s Consolidated Financial Position, 2006 and 2007

Table 6.6: Actelion’s Geographic Information, 2006 and 2007

Table 6.7: Arena’s Independent and Partnered Research Programs, 2007

Table 6.8: Cephalon’s Product Profile, 2007

Table 6.9: Eli Lilly’s Net Sales Activity, 2007

Table 6.10: Trade Marks of Eli Lilly’s Products, 2007

Table 6.11: King’s Product Portfolio, 2007

Table 6.12: King’s Summary of Net Revenues by Operating Segment, 2005-2007

Table 6.13: King’s Branded Prescription Products

Table 6.14: Neurogen’s Clinical Development Programs, 2007

Table 6.15: Mean LPS in Minutes

Table 6.16: Neurocrine’s Product Pipeline

Table 6.17: Pfizer’s R&D Pipeline, 2008

Table 6.18: Pfizer’s Revenue by Product, 2006 and 2007

Table 6.19: Pfizer’s Revenue from Major Pharmaceutical Products, 2005-2007

Table 6.20: Recent FDA Approved Products from Pfizer, 2007

Table 6.21: Pfizer’s Pending New Drug Applications (NDAs) and Supplemental Filings in U.S., 2007

Table 6.22: Regulatory Approvals and Filings in the E.U. and Japan

Table 6.23: Pfizer’s Revenue by Geographic Region, 2005-2007

Table 6.24: Pfizer’s Revenue by Therapeutic Area, 2005-2007

Table 6.25: Sanofi’s Pharmaceutical and Human Vaccine Business, 2007

Table 6.26: Sanofi’s R&D, 2007

Table 6.27: Sanofi’s Vaccine Pipeline, 2007

Table 6.28: Net Sales of Schering-Plough’s Products, 2005-2007

Table 6.29: Sepracor’s Products and Pipeline, 2007

Table 6.30: Sepracor’s Launch and Target Launch Dates, 1999-2014

Table 6.31: Sepracor’s Selected Financial Data, 2003-2007

Table 6.32: SleepMed’s Self-test Questionnaire

Table 6.33: SleepMed’s Sleep Assessment Form

Table 6.34: Sleepiness Scale

Table 6.35: Silenor Clinical Program

Table 6.36: Takeda’s Global Locations, 2008

Table 6.37: Takeda’s Net Sales by Region, 2006-2008

Table 6.38: Takeda’s R&D Pipeline, 2008

Table 6.39: Takeda’s R&D Pipeline, 2007

Table 6.40: Takeda’s In-Licensing and Alliance Activities, 2007

Table 6.41: Number of Employees in Takeda, 2006-2008

Table 6.42: Vanda’s Candidates in Clinical Development

Table 6.43: Wyeth’s Pipeline of Products, 2007

Table A1.1: Age-adjusted Percentages of Adults Engaged in Selected Health Risk Behaviors by Hours of Sleep in the U.S., 2004-2006

Table A1.2: Age-adjusted Percentages of Adults Engaged in Selected Health Risk Behavior by Sex and Hours of Sleep in the U.S., 2004-2006

Table A1.3: Age-adjusted Percentages of Adults Engaged in Selected Health Risk Behaviors by Age and Hours of Sleep in the U.S., 2004-2006

Table A2.1: Most Common Adverse Events Occurring in At least Five Percent of Patients

Table A4.1: Sample BMIs for Weight and Height Ranges

Table A4.2: U.S. Obesity Rates, 2007

Table A4.3: Demographic Statistics of a Pediatric Surgical Population in the U.S.

Table A5.1: Physiological Changes during NREM and REM Sleep

Table A5.2: Percent Sleep for Young Children

Table A5.3: Percent Sleep for Young Adults

Table A5.4: Percent Sleep for Elderly Adult

Table A6.1: Current Sleep-related Clinical Trials

Table A6.2: Just Completed and On-going Clinical Trials for Circadian Rhythm Sleep Disorders

Abstract

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.